Clinical Trials
115 trialsABBY
Abramson Cancer Center at Penn Medicine
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
TAPUR
American Society of Clinical Oncology
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
I-SPY
QuantumLeap Healthcare Collaborative
ALEPRO
Universitaire Ziekenhuizen KU Leuven
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Memorial Sloan Kettering Cancer Center
ETHAN - ET for Male BC
Dana-Farber Cancer Institute
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Dana-Farber Cancer Institute
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
Fudan University
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
FAIM
Royal Marsden NHS Foundation Trust
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Alliance for Clinical Trials in Oncology
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
UPLIFT
University of California, San Francisco
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
University of Washington
EndoMAP
Alliance Foundation Trials, LLC.
ABBICAR
Universitaire Ziekenhuizen KU Leuven
Clinical and P
Beni-Suef University
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Abemaciclib in Newly Diagnosed Meningioma Patients
St. Joseph's Hospital and Medical Center, Phoenix
CARABELA
Spanish Breast Cancer Research Group
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
St. Joseph's Hospital and Medical Center, Phoenix
Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma
M.D. Anderson Cancer Center
MiRaDoR
MedSIR
VIOLET
Mario Negri Institute for Pharmacological Research
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Dana-Farber Cancer Institute
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
Dana-Farber Cancer Institute
Abemaciclib With or Without Atezolizumab for mCRPC
Dana-Farber Cancer Institute
Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Breast Cancer
Fudan University
DISCORDANT
Danish Breast Cancer Cooperative Group
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
OHSU Knight Cancer Institute
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
The Methodist Hospital Research Institute
GERTRUDE
Dartmouth-Hitchcock Medical Center
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
Dana-Farber Cancer Institute
Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors
University of Washington
POETIC-A
Institute of Cancer Research, United Kingdom
BRE-09
University of Illinois at Chicago
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center